TH99533B - Formulation of marigold extract in liposome cream form and preparation method. - Google Patents

Abstract

DC60 (April 25, 2013) This invention relates to marigold extract in the form of a liposomal cream for topical application. The disclosure describes the formulation of the liposomal encapsulated marigold extract and its preparation method. The liposomal particles are composed of saturated phosphatidylcholine phospholipid derived from soybeans and cholesterol in a molar ratio of 15:1, and marigold extract. The preparation method is phase reversal evaporation followed by ultrasonic particle size reduction to obtain uniform liposomal particle sizes ranging from 0.01-0.5 microns. This liposomal encapsulated marigold extract suspension is intended as a topical UV protection product, representing an alternative prototype for cosmetic applications. This invention relates to marigold extract in the form of a liposomal cream for topical application, and the disclosure describes the formulation of the liposomal encapsulated marigold extract and its preparation method. The liposome particles are composed of saturated phosphalicylcholine lipid derived from soybeans and cholesterol in a molar ratio of 15:1, along with marigold extract. The preparation method involved phase reversal evaporation followed by particle size reduction using ultrasonic waves to obtain uniform liposome particle sizes ranging from 0.01-0.5 microns. This liposome containing marigold extract in suspension form is intended as a topical UV protection product, representing an alternative product for cosmetic applications.

Claims (5)

OCR 29/11/2566 1. A formulation of marigold extract in liposome cream form containing: a) Marigold extract, 0.01 - 1.00% by weight; b) Hydrogenated phosphatidylcholine, 0.50 - 1.00% by weight; c) Cholesterol, 0.01 - 0.05% by weight; d) Deionized water, 97.00 - 99.00% by weight. 2. A formulation of marigold extract in liposomal cream form as per claim 1, in which the marigold extract contains the active ingredient quercetagetin in the range of 1% to 30%. 3. A formulation of marigold extract in liposomal cream form, as per claim 1, in which the phosphatidylcholine is saturated phosphatidylcholine derived from soybeans. 4. The procedure for formulating marigold extract in liposomal cream form, according to any one of claims 1 through 3, consists of the following steps: a) Prepare the oil phase by mixing 117-200 mg of saturated phosphatidylcholine, 3.5-5.0 mg of cholesterol, 18-20 ml of dichloromethane, 2-4 ml of methanol, and 3-5 mg of marigold extract in a 250 ml round bottle. b) Prepare the water phase by mixing 5 ml of deionized water with the oil phase to achieve homogeneity using sound waves in a vibrating water bath at 4-8 °C for 15 minutes. This will result in an oil-water emulsion mixture. c) Evaporate the organic solvent from the mixture obtained from step b) using a rotary vacuum evaporator at 35 °C. The final step will yield a cloudy yellowish emulsion. Adjust the volume of this emulsion with deionized water to achieve the desired consistency. The final volume is 20 milliliters. d) The resulting solution is further reduced in particle size using sound waves in a vibrating system with a titanium ultrasonic emitter for 6 minutes at an amplitude of 30%. This yields a marigold extract for transdermal delivery in the form of a liposome suspension. 5. The use of marigold extract formulations in liposomal cream formulations as per any of claims 1 through 3 may be achieved by incorporating them into cosmetic products in cream or gel form for topical application to humans.